Figure 2.

Alteration of miRNAs expression is associated with stemness, EMT, proliferation, metastasis, and apoptosis through targeting several endogenous molecules that contribute to the carcinogenesis of TNBC. PTEN—phosphate and tensin homology, TRPS1—trichorhinophalangeal 1, ADIPOR1—adiponectin receptor 1, CCAAT—enhancer binding protein beta (C/EBPβ), FN1—fibronectin 1, MSN—moesin, NTRK2 or TrkB—neurotrophic tyrosine receptor kinase type 2, LEPR—leptin receptor, ARHGAP19—Rho GTPase activating protein 19, BCSC—breast cancer stem cell, ATM—Ataxia telangiectasia mutated, FOXP2—factor Forkhead-box P2, HMGA2—high-mobility group A protein 2, BT-ICs—breast tumor-initiating cells, Ubc9—ubiquitin-conjugating enzyme 9, ITGB3 (integrin beta3, CSC—cancer stem cell, IGFII—insulin-like growth factor II (mRNA binding protein (IMP3), SETDB1—SET domain bifurcated 1, PFN1—profilin 1, LIFR—leukemia inhibitory factor receptor, EI24—etoposide induced 2.4, APC—adenomatous polyposis coli, XIAP—X linked inhibitor of apoptosis, UBASH3B—ubiquitin-associated and SH3 domain-containing B, v-myc—myelocytomatosis viral oncogene homolog (c-Myc), ZEB1—zinc finger E-box binding homeobox 1, ARF—ARF proteins, MUC1—Mucin1, CORO1C—Coronin 1C, RoR—regulator of reprogramming, ROR1—RTK-like orphan receptor 1, RGS3—G protein signaling 3, BTG2—B-cell translocation gene 2, RUNX3—runt-related transcription factor 3, BIRC5—baculoviral IAP repeat-containing protein 5, LASP1—Lim and SH3 domain protein 1, EZH2—enhancer of Zeste homolog 2, MTDH—Metadherin, AEG-1—astrocyte elevated gene 1, TNKS2—tankyrase 2, LIMK1—LIM kinase-1, LIMK2—LIM kinase-2, ETV1- ETS variant 1, LAMA4—laminin subunit alpha 4, KLF5—Krüppel-like factor 5, MTA2—metastasis-associated protein 2, RIP1—receptor-interacting protein 1, CYLD—cylindromatosis, DR4/5death receptor 4/5, SOCS1—cytokine signaling 1, cIAP1—cellular inhibitor of apoptosis.